Gaudium IVF & Women’s Health’s initial public offering (IPO) opened on February 20, 2026, and early demand shows growing investor interest. By mid-day, the issue was 63% subscribed in the retail segment, while the overall subscription crossed 38%. The company aims to raise ₹165 crore at a price band of ₹75 to ₹79 per share.
Adding to the optimism, the grey market premium (GMP) stood near ₹11-₹15, signaling a possible strong listing. Gaudium IVF operates in the fast-growing fertility and women’s healthcare space, which continues to see rising demand across India. With solid fundamentals, expanding operations, and early market traction, this IPO has quickly become one of the most closely watched healthcare offerings of February 2026.
Advertisement
Gaudium IVF IPO Snapshot – Key Details at a Glance
What are the key details of Gaudium IVF IPO?
Gaudium IVF & Women’s Health launched its ₹165 crore IPO on February 20, 2026, targeting investors across retail, HNI, and institutional segments. The company aims to fund expansion and reduce debt through this public issue.
Key IPO Details:
- IPO size: ₹165 crore
- Fresh issue: ₹90 crore
- Offer for Sale (OFS): ₹75 crore
- Price band: ₹75 to ₹79 per share
- Lot size: 189 shares
- Minimum investment: ₹14,931
- Listing exchanges: BSE and NSE
Important Dates:
- Opening date: February 20, 2026
- Closing date: February 24, 2026
- Allotment date: February 25, 2026
- Listing date: February 27, 2026
Subscription Status – Retail Investors Lead the Demand
How much has the Gaudium IVF IPO been subscribed to so far?
On Day 1, February 20, 2026, Gaudium IVF IPO showed strong early traction, driven mainly by retail investors.
Subscription Status (as of mid-day):
- Overall subscription: 38-40%
- Retail investors (RII): 63-77%
- Non-institutional investors (NII): 34-42%
- Qualified institutional buyers (QIB): Yet to pick up
Retail demand remained strong throughout the first half of the day, indicating solid interest from small investors. This trend reflects growing confidence in the fertility and women’s healthcare sector, especially among long-term investors.
GMP Trend – What Grey Market Premium Signals About Listing
What is the latest GMP of Gaudium IVF IPO?
The grey market premium (GMP) for Gaudium IVF IPO stood between ₹11 and ₹15 on February 20, 2026, suggesting a moderate premium listing.
Recent GMP Trend:
- Feb 18: ₹15
- Feb 19: ₹12
- Feb 20: ₹11
Based on the upper price band of ₹79, the estimated listing price may range between ₹90 and ₹94, implying 13-18% listing gains. However, investors should note that GMP reflects market sentiment, not guaranteed performance. Market conditions on listing day also play a major role.
Anchor Investor Confidence – ₹49.5 Cr Raised Before IPO
Why does anchor investor participation matter?
Ahead of the IPO launch, Gaudium IVF raised ₹49.5 crore from anchor investors on February 19, 2026, which boosted overall investor confidence.
Anchor Round Highlights:
- Amount raised: ₹49.5 crore
- Shares allocated: 62.65 lakh
- Price: ₹79 per share (upper band)
Anchor investment shows strong institutional trust in the company’s business model and growth prospects. It also helps stabilize price action during the early trading sessions.
Business Model & Growth Potential of Gaudium IVF
What does Gaudium IVF do, and why is its business scalable?
Gaudium IVF operates in the fertility treatment and women’s healthcare segment, offering IVF, IUI, ICSI, and ovulation induction services.
Key Business Highlights:
- Founded: 2015
- Operating centers: 30+ locations
- Model: Hub-and-spoke
- Cities covered: Delhi, Mumbai, Bengaluru, Patna, Srinagar, Ludhiana
- International patients: UK, USA, Canada, Kenya, Oman
India’s IVF market is expected to grow at a 15-18% CAGR through 2030, driven by rising infertility cases, late marriages, lifestyle changes, and growing awareness. This makes Gaudium IVF well-positioned for long-term structural growth.
Use of IPO Proceeds – Where Will the Funds Go?
How will Gaudium IVF use the IPO money?
According to its Red Herring Prospectus (RHP), the company plans to use IPO proceeds mainly for expansion and debt reduction.
Fund Allocation Plan:
- ₹50 crore: Set up new IVF centers
- ₹20 crore: Repay existing borrowings
- Remaining: General corporate purposes
The company aims to open 19 new IVF centers by FY29, which supports revenue growth and improves regional presence.
Expert Reviews & Brokerage Outlook
What do analysts say about the Gaudium IVF IPO?
Several brokerages have given a “Subscribe” rating, citing strong fundamentals and sector tailwinds.
Brokerage Opinions:
- SMIFS: Positive on scalable model and growth outlook
- BP Equities: Strong financial performance and long-term growth visibility
- Ventura Securities: High operating margins, strong execution track record
Valuation stands at around 25x FY25 earnings, which analysts find reasonable considering growth prospects.
Data-Driven Insights & AI Market Analysis
Advanced AI stock analysis tools highlight Gaudium IVF’s low debt, improving profit margins, and expanding capacity as key positive signals. These data-backed insights help investors assess listing strength and medium-term performance.
Such tools analyze real-time subscription trends, GMP movement, financial ratios, and sector data to provide objective investment signals.
Conclusion – Should Investors Track Gaudium IVF IPO Closely?
Gaudium IVF IPO shows strong retail demand, healthy GMP, and solid institutional backing. Its business model, sector growth, and expansion plans add long-term value.
With the listing scheduled for February 27, 2026, investor focus will remain on final subscription numbers and broader market sentiment. For both listing gains and medium-term exposure, this IPO remains one of February 2026’s most-watched healthcare offerings.
Advertisement
Frequently Asked Questions (FAQs)
As of February 20, 2026, the Gaudium IVF IPO is 63% subscribed in the retail segment. Overall subscription is around 38-40%. Retail investors are showing strong interest so far.
The grey market premium (GMP) for Gaudium IVF IPO is ₹11–₹15 on February 20, 2026. This indicates moderate positive sentiment and possible listing gains.
Gaudium IVF IPO shows strong early demand and solid fundamentals. It looks promising for listing gains. Investors should still track subscription and market conditions before deciding.
Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.
Advertisement
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)